CHRS Stock Overview
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Coherus BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.02 |
| 52 Week High | US$8.22 |
| 52 Week Low | US$1.43 |
| Beta | 0.51 |
| 1 Month Change | -11.40% |
| 3 Month Change | -14.77% |
| 1 Year Change | -73.10% |
| 3 Year Change | -86.31% |
| 5 Year Change | -87.34% |
| Change since IPO | -83.98% |
Recent News & Updates
Recent updates
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Mar 21Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive
Feb 03
Coherus BioSciences: FDA Approvals Spice Up The Pipeline
Jan 17Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues
Dec 20The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically
May 13Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3
Sep 19Coherus: 2022 Is In Many Ways A Make Or Break Year
Aug 24Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli
Aug 03Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer
Jul 06Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?
Jun 15Coherus: Will Its Chinese Gambit Fail?
May 27Is Coherus BioSciences (NASDAQ:CHRS) Using Debt In A Risky Way?
Jan 06Shareholder Returns
| CHRS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.0% | 1.0% | 1.2% |
| 1Y | -73.1% | 0.7% | 24.9% |
Return vs Industry: CHRS underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: CHRS underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| CHRS volatility | |
|---|---|
| CHRS Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CHRS's share price has been volatile over the past 3 months.
Volatility Over Time: CHRS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 306 | Denny Lanfear | www.coherus.com |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME.
Coherus BioSciences, Inc. Fundamentals Summary
| CHRS fundamental statistics | |
|---|---|
| Market cap | US$247.43m |
| Earnings (TTM) | -US$237.89m |
| Revenue (TTM) | US$257.24m |
0.9x
P/S Ratio-1.0x
P/E RatioIs CHRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHRS income statement (TTM) | |
|---|---|
| Revenue | US$257.24m |
| Cost of Revenue | US$158.99m |
| Gross Profit | US$98.25m |
| Other Expenses | US$336.14m |
| Earnings | -US$237.89m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.10 |
| Gross Margin | 38.19% |
| Net Profit Margin | -92.48% |
| Debt/Equity Ratio | -244.7% |
How did CHRS perform over the long term?
See historical performance and comparison